These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37531032)

  • 61. Atogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman JM
    Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent Advances in Pharmacotherapy for Episodic Migraine.
    Chan C; Goadsby PJ
    CNS Drugs; 2019 Nov; 33(11):1053-1071. PubMed ID: 31556018
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.
    de Boer I; Verhagen IE; Souza MNP; Ashina M
    Cephalalgia; 2023 Feb; 43(2):3331024221143773. PubMed ID: 36739516
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C; Beier D; Martelletti P; Pellesi L
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine.
    Dodick DW; Ailani J
    J Fam Pract; 2020; 69(1 Suppl):S13-S22. PubMed ID: 32053715
    [No Abstract]   [Full Text] [Related]  

  • 67. Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.
    Holland PR; Goadsby PJ
    Neurotherapeutics; 2018 Apr; 15(2):304-312. PubMed ID: 29556965
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ubrogepant for the Treatment of Migraine.
    Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
    N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review.
    Takizawa T; Ihara K; Uno S; Ohtani S; Watanabe N; Imai N; Nakahara J; Hori S; Garcia-Azorin D; Martelletti P
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):951-967. PubMed ID: 37925645
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diagnosis and Management of Headache: A Review.
    Robbins MS
    JAMA; 2021 May; 325(18):1874-1885. PubMed ID: 33974014
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rimegepant for the treatment of migraine.
    Negro A; Martelletti P
    Drugs Today (Barc); 2020 Dec; 56(12):769-780. PubMed ID: 33332483
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
    Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardiovascular Disease and Migraine: Are the New Treatments Safe?
    Robblee J; Harvey LK
    Curr Pain Headache Rep; 2022 Aug; 26(8):647-655. PubMed ID: 35751798
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine.
    Caronna E; Starling AJ
    Neurol Clin; 2021 Feb; 39(1):1-19. PubMed ID: 33223077
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants].
    Mínguez-Olaondo A; López-Bravo A; Quintas S; Nieves-Castellanos C; Layos-Romero A; Belvís R; Irimia P; Díaz-Insa S
    Rev Neurol; 2024 Jan; 78(2):47-57. PubMed ID: 38223948
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 79. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Situational prevention in migraine: are we doing the right thing?
    Pellesi L; Martelletti P
    J Headache Pain; 2024 Aug; 25(1):137. PubMed ID: 39174943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.